Iradimed Corp (IRMD) VP Sells $45,060.00 in Stock

Iradimed Corp (NASDAQ:IRMD) VP Brent Johnson sold 2,000 shares of Iradimed stock in a transaction on Monday, May 20th. The stock was sold at an average price of $22.53, for a total value of $45,060.00. Following the completion of the sale, the vice president now directly owns 4,368 shares of the company’s stock, valued at approximately $98,411.04. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Brent Johnson also recently made the following trade(s):

  • On Friday, May 17th, Brent Johnson sold 3,000 shares of Iradimed stock. The stock was sold at an average price of $21.83, for a total value of $65,490.00.
  • On Wednesday, March 13th, Brent Johnson sold 52,492 shares of Iradimed stock. The stock was sold at an average price of $24.42, for a total value of $1,281,854.64.
  • On Monday, March 11th, Brent Johnson sold 17,033 shares of Iradimed stock. The stock was sold at an average price of $25.38, for a total value of $432,297.54.
  • On Wednesday, March 6th, Brent Johnson sold 9,672 shares of Iradimed stock. The stock was sold at an average price of $24.58, for a total value of $237,737.76.

Shares of IRMD stock traded down $1.25 on Thursday, reaching $21.11. The stock had a trading volume of 10,949 shares, compared to its average volume of 81,545. The company has a market cap of $249.54 million, a P/E ratio of 49.09 and a beta of 1.70. Iradimed Corp has a 1 year low of $18.20 and a 1 year high of $38.78. The company has a debt-to-equity ratio of 0.06, a current ratio of 9.48 and a quick ratio of 8.63.

Iradimed (NASDAQ:IRMD) last released its quarterly earnings results on Tuesday, April 30th. The medical equipment provider reported $0.11 earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of $0.11. The firm had revenue of $8.44 million for the quarter, compared to the consensus estimate of $8.38 million. Iradimed had a return on equity of 13.98% and a net margin of 23.00%. As a group, analysts expect that Iradimed Corp will post 0.64 earnings per share for the current year.

A number of research firms have recently issued reports on IRMD. BidaskClub downgraded Iradimed from a “buy” rating to a “hold” rating in a research note on Thursday, May 9th. Zacks Investment Research upgraded Iradimed from a “hold” rating to a “buy” rating and set a $28.00 price target on the stock in a research note on Tuesday, May 7th. Finally, ValuEngine downgraded Iradimed from a “buy” rating to a “hold” rating in a research note on Wednesday, May 1st. Two investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $31.50.

Several hedge funds have recently added to or reduced their stakes in the company. Renaissance Technologies LLC boosted its stake in shares of Iradimed by 8.0% in the 1st quarter. Renaissance Technologies LLC now owns 346,200 shares of the medical equipment provider’s stock worth $9,725,000 after buying an additional 25,700 shares during the last quarter. BlackRock Inc. lifted its position in Iradimed by 6.2% during the first quarter. BlackRock Inc. now owns 341,550 shares of the medical equipment provider’s stock valued at $9,595,000 after purchasing an additional 19,930 shares in the last quarter. Vanguard Group Inc. lifted its position in Iradimed by 19.7% during the third quarter. Vanguard Group Inc. now owns 250,298 shares of the medical equipment provider’s stock valued at $9,298,000 after purchasing an additional 41,184 shares in the last quarter. Vanguard Group Inc lifted its position in Iradimed by 19.7% during the third quarter. Vanguard Group Inc now owns 250,298 shares of the medical equipment provider’s stock valued at $9,298,000 after purchasing an additional 41,184 shares in the last quarter. Finally, Ranger Investment Management L.P. lifted its position in Iradimed by 13.3% during the fourth quarter. Ranger Investment Management L.P. now owns 190,226 shares of the medical equipment provider’s stock valued at $4,653,000 after purchasing an additional 22,341 shares in the last quarter. Hedge funds and other institutional investors own 23.01% of the company’s stock.

WARNING: This story was first published by Baseball Daily News and is the sole property of of Baseball Daily News. If you are viewing this story on another website, it was copied illegally and reposted in violation of US & international trademark and copyright legislation. The original version of this story can be accessed at https://www.baseballdailydigest.com/news/2019/05/23/iradimed-corp-irmd-vp-sells-45060-00-in-stock.html.

Iradimed Company Profile

IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices, and related accessories and services in the United States and internationally. It offers MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets; and MRI compatible patient vital signs monitoring system.

Recommended Story: Is the Dow Jones Industrial Average (DJIA) still relevant?

Insider Buying and Selling by Quarter for Iradimed (NASDAQ:IRMD)

Receive News & Ratings for Iradimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iradimed and related companies with MarketBeat.com's FREE daily email newsletter.